nct_id: NCT06137118
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-11-18'
study_start_date: '2023-12-29'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: AZD0486'
long_title: A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent
  and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia
last_updated: '2025-10-20'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: AstraZeneca
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 142
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Age: 12 years and above (Parts A, B and C).'
- '* Participants with B-cell Acute Lymphoblastic Leukemia with CD19 expression by
  local lab with:'
- 1. Bone marrow infiltration with \>/= 5% blasts
- 2. Either relapsed or refractory after a minimum of 2 prior therapies or after 1
  prior line of therapy if no SOC available option.
- 3. Philadelphia positive participants are allowed in all parts of the study, if
  intolerant or refractory to TKIs.
- '* For participants older than 16 years, Eastern Cooperative Oncology Group (ECOG)
  Performance Status less than or equal to 2. For Participants 16 years or younger,
  Lansky score more or equal to 50%.'
- The above is a summary, other inclusion criteria details may apply.
- 'Exclude - Exclusion Criteria:'
- Exclude - * Active CNS involvement by B-ALL, defined by presence of ALL blasts in
  CSF (CNS2 and CNS3 criteria).
- Exclude - * Isolated extramedullary disease relapse.
- Exclude - * Testicular leukemia
- Exclude - * History or presence of clinically relevant CNS pathology such as epilepsy,
  seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's
  disease, cerebellar disease, organic brain syndrome, or psychosis; or prior Grade
  4 neurotoxicity with CAR-T or TCE therapy.
- Exclude - * History of other malignancy (with certain exceptions).
- Exclude - * Unresolved AEs \>/= Grade 2, from prior therapies
- Exclude - * Prior therapy with TCEs within 4 weeks, CAR T-cell therapy or autologous
  HSCT within 8 weeks or prior alloSCT within 12 weeks of start of therapy.
- Exclude - * GVHD requiring immunosuppressive therapy within 3 weeks prior to AZD0486
  treatment.
- Exclude - The above is a summary, other exclusion criteria details may apply.
short_title: AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: AstraZeneca
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: "This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation\
  \ and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and\
  \ efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received\
  \ \u2265 2 prior lines of therapies. The study will consist of 3 parts. Part A monotherapy\
  \ dose escalation. Part B dose optimisation. Part C Dose expansion at the recommended\
  \ phase 2 dose (RP2D)"
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Part A: AZD0486 Dose Escalation'
      arm_internal_id: 0
      arm_description: Ascending dose level cohorts of AZD0486 in B-ALL participants
        aged 12 years and above.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AZD0486'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Part B: Dose Optimization'
      arm_internal_id: 1
      arm_description: Up to 2 cohorts will be evaluated prior declared safe-doses
        and schedules in order to determine the recommended phase 2 dose (RP2D). Participants,
        aged 12 years and above, will receive AZD0486 IV infusions and will be randomized
        in a 1:1 ratio.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AZD0486'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Part C: Dose Expansion'
      arm_internal_id: 2
      arm_description: Part C will consist of 1 cohort of participants aged 12 years
        and above, treated with the optimal dose selected in Part B and receive IV
        AZD0486 monotherapy.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AZD0486'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=12'
        disease_status:
        - Recurrent
        - Refractory
        oncotree_primary_diagnosis: Lymphoid Neoplasm
